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Chronic chagasic cardiomyopathy (CCC) is arguably the most important form of the Chagas Disease, 
caused by the intracellular protozoan Trypanosoma cruzi; it is estimated that 10–30% of chronic 
patients develop this clinical manifestation. The most common and severe form of CCC can be related 
to ventricular abnormalities, such as heart failure, arrhythmias, heart blocks, thromboembolic events 
and sudden death. Therefore, in this study, we proposed to evaluate the anti-angiogenic activity of 
a recombinant protein from T. cruzi named P21 (rP21) and the potential impact of the native protein 
on CCC. Our data suggest that the anti-angiogenic activity of rP21 depends on the protein’s direct 
interaction with the CXCR4 receptor. This capacity is likely related to the modulation of the expression 
of actin and angiogenesis-associated genes. Thus, our results indicate that T. cruzi P21 is an attractive 
target for the development of innovative therapeutic agents against CCC.
Chagas disease (also known as American trypanosomiasis) is caused by the intracellular parasite Trypanosoma 
cruzi and affects 8–10 million people worldwide being endemic in Latin America where approximately 109 mil-
lion individuals are at risk1. Chronic Chagasic Cardiomyopathy (CCC) is possibly the most important form of 
Chagas disease; it is estimated that 10–30% of chronic patients develop this clinical manifestation2. CCC is char-
acterized by morbidity and early mortality in the most productive age group, which has created an extensive 
economic and social burden in endemic areas3–5.
The most common and severe form of CCC can be related to ventricular abnormalities such as heart failure, 
arrhythmias, heart blocks, thromboembolic events and sudden death. It is estimated that 20,000 deaths occur 
annually in endemic areas due to CCC complications. Moreover, refractory heart failure and thromboembolism 
are the most important causes of death6. These clinical manifestations have contributed to Chagas disease becom-
ing one of the most important causes of heart disease7,8.
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The exact mechanism of CCC pathogenesis is complex and remains unclear. However, several studies have 
shown that CCC etiology is likely the result of a number of factors that involve the T. cruzi strain, including 
parasite-dependent myocardial damage9, persistent parasitemia10–12, immune-mediated myocardial injury (auto-
immunity)13 and host-related genetic factors14.
Our research group has recently characterized a recombinant protein from T. cruzi named P21 (rP21) as an 
attractive therapeutic target for CCC treatment. It has been shown that rP21 can recruit immune cells, induce 
myeloperoxidase and interleukin (IL)-4 production and decrease blood vessel formation compared to the con-
trols in vitro and in vivo15. Here we aimed to investigate the anti-angiogenic activity of rP21 in order to get novel 
insight into the potential impact of the native protein on the onset of chagasic cardiomyopathy.
Results and Discussion
Anti-angiogenic activity of rP21 depends on its direct interaction with endothelial cells. Our 
previous studies showed that a murine endothelial cell line (tEnd) treated with different concentrations of rP21 
did not exhibit altered cell viability or adhesion to a thin layer of extracellular matrix, but vessel formation was 
inhibited after 18 hours of incubation15. However, an intriguing question was raised: how does P21, a parasite-de-
rived molecule, significantly interfere with the angiogenesis process? Therefore, in this study we aimed to gain 
insight into the mechanism by which rP21 inhibits angiogenesis. Thus, we verified that the anti-angiogenic activ-
ity of rP21 was time-dependent and was observed at 24, 48 and 72 h (Fig. 1A). The significant decreases in the 
number of vessels in the control group at 48 and 72 h were due to the intense cellular proliferation that closed the 
vessels.
Moreover, we evaluated the influence of rP21 upon extracellular matrix (ECM) components and observed 
that the protein was not able to promote degradation of bovine fibrinogen, Matrigel or fibronectin compared 
to the control group (untreated), regardless of the protein quantity (Fig. 1B,C). In addition, to confirm whether 
the anti-angiogenic activity of rP21 occurs by a direct interaction with ECM components or by interaction with 
endothelial cells (ECs) we incubated the tEnd cells with rP21 and the cells were then washed out or not then 
plated on a thin ECM (Matrigel) layer. Our results showed that in both situations rP21 was able to inhibit the 
angiogenesis process indicating that this protein directly interacts with ECs (Fig. 1D).
ECM regulates different cellular processes including growth, migration, differentiation, survival, homeosta-
sis, and morphogenesis. ECM consists of a large variety of matrix macromolecules such as collagens, elastin, 
fibronectin (FN), laminins, glycoproteins, proteoglycans (PGs), and glycosaminoglycans (GAGs) that associate 
with each other to build the complex three-dimensional matrix network16,17. In this sense, Matrigel (a solubilized 
basement membrane-like composite from Engelbreth-Holm-Swarm sarcoma) was used as a surrogate for ECM 
and is mainly composed of laminin, type IV collagen, nidogen and heparan sulfate proteoglycans18. However, 
rP21 showed no detectable proteolytic activity on the matrix components (Fig. 1B,C).
Although rP21 did not interfere with EC adhesion or cellular viability15 and did not exhibit proteolytic activity 
on ECM components, this protein strongly inhibits vessel formation. This anti-angiogenic effect of rP21 could be 
explained by other mechanisms such as a direct interaction of rP21 with ECs. To test this hypothesis, we showed 
that rP21 binds to ECs and is internalized by these cells (Fig. 1E). These data suggest that the rP21-EC interaction 
can initiate a cascade of intracellular events that culminate in decreased vessel formation.
The rP21-CXCR4 interaction decreases blood vessel formation and inhibits EC prolifera-
tion. Our previous studies showed that rP21 has the capacity to bind to CXC receptor 4 (CXCR4; CD184), 
enhancing macrophage phagocytosis and actin polymerization19. Therefore, we performed additional experi-
ments to gain insights into the rP21-CXCR4 interaction in ECs. First, we showed that CXCR4 was highly 
expressed on the surface of tEnd cells (endothelial cells) (Fig. 2A). Then, to assess whether the rP21-mediated 
inhibition of vessel formation depends on its binding to the CXCR4 receptor, tEnd cells were treated with a 
receptor-specific antagonist, AMD3100 (CXCR4 inhibitor). We observed that blocking CXCR4 signaling path-
way and subsequent treatment with or without rP21 did not inhibit vessel formation compared to the other 
groups (Fig. 2B,C). Therefore, we suggest that the anti-angiogenic activity of rP21 depends on its interaction with 
CXCR4.
CXCL12 [stromal cell-derived factor-1 (SDF-1)] is a chemokine and primarily binds to CXCR4. CXCL12 
secretion is associated with tissue damage such as heart infarction and focal ischemia to promote vessel repair. 
CXCR4 is expressed by T-lymphocytes, B-lymphocytes, macrophages, neutrophils, and endothelial and epithelial 
cells. This receptor is widely expressed by ECs in damaged tissues such as injured carotid arteries and atheroscle-
rotic plaques during pathological processes20,21. It is known that pro-angiogenic CXCR4+ cells are recruited to 
damaged tissues along a CXCL12 gradient to promote the re-vascularization of the injured areas demonstrating 
the importance of the CXCL12/CXCR4 pathway during inflammatory processes22.
A hallmark of CCC is an intense inflammatory process that is clinically persistent in indeterminate and 
chronic chagasic patients and is essentially characterized by myocarditis23. The prevalence of myocarditis cor-
relates with the severity of clinical heart failure such as vasospasms, decreased blood flow, myocardial ischemia, 
coronary angiography, impairment of endothelium-dependent coronary vasodilatation, platelet thrombi 
and increased platelet aggregation24–28. The micro-vascular ischemia observed during CCC may be partially 
explained by the active role of P21. Intracellular, trapped parasites may constantly secrete P21 that can gain access 
to the extracellular space and bind to CXCR4+ ECs from the heart that would lose their capacity to promote 
re-vascularization in situ contributing to disease progression. This hypothesis is partially supported by several 
independent studies showing that the persistence of T. cruzi is directly associated with CCC pathogenesis. For 
example, Andrade et al.29 and Silva et al.30 reported that an enhanced parasite burden exacerbates the cardiomy-
opathy course. Moreover, Añes et al.31 showed that intact amastigotes are able to survive and multiply inside host 
heart tissue during the chronic phase contributing to disease progression.
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The CXCR4-CXCL12 axis is widely known to promote EC multiplication32–35. In this context, we proposed 
to assess the influence of rP21 on EC proliferation. EC cell growth curve showed a decrease in all time points of 
rP21 treatment (Fig. 3A). Moreover, MTT assay demonstrated that while the combination of fetal bovine serum 
(FBS) and basic fibroblastic growth factor (bFGF) saturated EC proliferation capacity, rP21 inhibited EC prolif-
eration at 24, 48 and 72 h post-treatment (Fig. 3B). This anti-proliferative activity of rP21 was confirmed by cell 
cycle analysis where we observed a significant decrease in the 2N cell number and an increase in the number of 
cell in S phase up to 72 h (Fig. 3C), raising the possibility that the anti-proliferative activity of rP21 can be related 
to replicative stress. Taken together, these results suggest that rP21 antagonizes CXCL12 activity. The subsequent 
mechanisms by which rP21 inhibits cell proliferation will be thoroughly evaluated in future studies from our 
research group.
rP21 induces actin cytoskeleton polymerization and modulates the expression of actin-related 
genes in endothelial cells. Actin is a major cytoskeletal component of ECs and is a well-studied cytoskeletal 
element that controls angiogenesis36. The actin cytoskeleton orchestrates various steps in both physiological and 
Figure 1. Anti-angiogenic activity of rP21 depends on its direct interaction with endothelial cells. (A) rP21 
inhibited angiogenesis in vitro in a time-dependent manner at 24, 48 and 72 h. (B) rP21 was incubated with 
50 μ L of different substrates for 1 h at 37 °C. 1 Bovine fibrinogen. 2–5 Bovine fibrinogen incubated with 5, 10, 
20 and 40 μ g of rP21, respectively. (C) 1 Matrigel control (without rP21). 2 Matrigel incubated with 40 μ g of 
rP21. 3 Fibronectin solution (without rP21). 4 Fibronectin incubated with 40 μ g of rP21. rP21 was not able to 
promote the degradation of the ECM components. (D) tEnds cells pre-incubated with rP21 were washout with 
PBS and centrifuged. The mechanical removal of rP21 post-treatment did not interfere with its anti-angiogenic 
activity in cells grown on a thin layer of ECM (Matrigel). (E) rP21 binds to ECs and is internalized by these cells. 
The data are expressed as the means ± standard deviations of experiments performed in triplicate. Significant 
differences were determined using Student’s t-test (two-sided) and Mann-Whitney test (A) and one-way 
ANOVA and Tukey’s multiple comparisons test (B). Differences were considered significant when p < 0.05. 
kDa: kilo Daltons. rP21 = 18 kDa. AlexaFluor 488 (rP21 label). Bars: 20 μ m.
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pathological angiogenesis which require continuous cytoskeletal-dependent remodeling37,38. Thus, the actin network 
and its associated proteins integrate with and respond to key signaling pathways known to regulate angiogenesis39.
To investigate the influence of rP21 on the actin cytoskeleton of ECs, we treated tEnd cells with different con-
centrations of rP21 and observed that rP21 significantly increased F-actin levels in ECs compared to the controls 
(not treated) using fluorescence microscopy (Fig. 4A,B). The effect of rP21 on the F-actin level may be due to an 
increase in the rate of actin polymerization, a decrease in actin depolymerization or both. To assess which of these 
processes are regulated by rP21, we performed an F-actin recovery assay using cytochalasin-D (CytD). tEnd cells 
were treated with CytD (1.5 μ M) for 40 min to inhibit actin subunit assembly followed by a recovery period in the 
presence or absence of rP21. We observed that rP21 increased the recovery rate of the actin filaments compared 
to the control groups. Thus, these results showed that rP21 has a remarkable capacity to promote actin polymeri-
zation in accordance with our previous studies19 (Fig. 4C).
The rP21-treated tEnd cells had markedly different actin cytoskeleton morphology compared to the control 
cells. ECs exhibited long, thick actin stress fibers that were aligned along cell longitudinal axis, and the plasma 
membrane was aligned with the bright phalloidin staining. In contrast, control cells had wispy, short actin fila-
ment bundles, and their plasma membrane was weakly stained with phalloidin. Moreover, rP21-treated tEnd 
cells exhibited sites of lamellipodial membrane protrusions enriched in F-actin compared to the control group 
(Fig. 4D - white arrows).
To gain insights into the direct effect of rP21 on actin cytoskeleton dynamics, tEnd cells were seeded 
into 24-well plates and incubated with rP21 or culture medium (control group) for 24 and 72 h and actin 
cytoskeleton-related gene expression was analyzed. rP21 modulated the expression levels of 7 important genes 
involved in a number of different biological effects such as cell motility, migration, morphogenesis, cell-cell inter-
actions and cell-ECM component interactions. rP21 up-regulated the expression of actin filament-associated 
protein 1-like 1 (AFAP1L1), cofilin, cortactin, fascin, profilin-1 and down-regulated the expression of ezrin and 
actin filament-associated protein 110 kilodaltons (kDa) in size (AFAP-110/AFAP1) at 24 h. Interestingly, at 72 h 
Figure 2. rP21-CXCR4 interaction decreases blood vessel formation. (A) tEnd cells showed increased 
CXCR4 expression on their surface. (B) rP21 depends on its direct binding to the CXCR4 receptor to inhibit 
vessel formation. (C) Representative phase contrast images of the organization of the tEnd cells in the Matrigel 
tube formation assay are shown. Data are shown as means ± SEM obtained from four independent experiments 
performed in triplicate. Significant differences were determined using one-way ANOVA and Tukey’s multiple 
comparisons test. Differences were considered significant when p < 0.05. Bars: 20 μ m.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:44978 | DOI: 10.1038/srep44978
of rP21 treatment we observed a turnover in gene expression with the exception of cofilin, profilin-1, ezrin and 
cortactin (Fig. 5A). Moreover, rP21 did not alter the expression of gelsolin, moesin and actin-related proteins 2 
and 3 (ARP2/3) complex genes (data not shown).
In this context, we examined whether changes in the mechanical properties of the substrate could promote 
the same effects on the expression of genes related to the actin cytoskeleton in rP21-treated ECs. Thus, tEnd cells 
were plated in 24-well plates that had been previously coated with a thin layer of ECM. After 24 and 72 h of treat-
ment with or without rP21, total RNA was extracted and analyzed by real-time PCR (RT-qPCR). We observed 
different gene expression profiles between two-dimensional (2-D) and three-dimensional (3-D) cell cultures. At 
24 h of treatment in 3-D cultures, rP21 promoted a slight down-regulation of AFAP1 and ARP2 expression and 
up-regulated gelsolin and moesin expression. Curiously, after 72 h rP21 only promoted down-regulated AFAP1, 
AFAP1L1, ezrin and moesin expression (Fig. 5B). Cofilin, cortactin, fascin, profilin-1 and ARP3 gene expression 
levels were not modulated by rP21 in the 3-D culture model (data not shown).
Dynamic regulation of the actin cytoskeleton plays a central role in a variety of cellular events and involves a 
number of actin-binding proteins (ABPs) including capping, branching, severing, sequestering, and cross-linking 
proteins40. Cofilin is a small ubiquitous protein that is able to bind both monomeric (G) and filamentous (F) actin. 
The F-actin-severing protein cofilin is a key player that regulates the dynamics of actin polymerization and depo-
lymerization in migrating cells41–45. Several studies have shown that cofilin is required to determine the direction 
of cell migration through actin polymerization-based protrusions42,46,47. Cortactin, another ABP, is located in the 
cytoplasm of cells and is associated with the polymerization and rearrangement of actin cytoskeleton, mainly 
at the periphery of the cellular cortex48,49. This protein actively triggers lamellipodia, protrusions of the plasma 
membrane that are characterized by high F-actin levels. Similar to cofilin, cortactin is also involved in cell motil-
ity50. Fascin is an actin cross-linking protein located in the actin-rich protrusions of ECs and is involved in the 
regulation of cytoskeletal scaffolds during cell adhesion and migration51.
AFAP1 and AFAP1L1 are members of the AFAP family of proteins; as adaptor proteins (non-enzymatic 
proteins) associated with the assembly and disassembly of the actin cytoskeleton52,53, these proteins affect cell 
adhesion, invasion and motility54. Snyder et al.55 showed that AFAP1 and AFAP1L1 overexpression promoted 
lamellipodia formation in the absence of extracellular signals. Moreover, these results indicate that AFAP1L1, 
like AFAP1, is associated with actin-stress fiber formation. In their report, the authors showed that AFAP1L1 but 
not AFAP1 binds cortactin to form a complex. Thus, these proteins may have the capacity to interact with differ-
ent proteins involved in actin cytoskeleton dynamics. Ezrin, radixin and moesin, which form the ERM protein 
family, act as linkers between the plasma membrane and the cortical actin filaments and are involved in many 
Figure 3. rP21 inhibits EC proliferation and interferes in cell cycle. (A) Growth curve of tEnd cells in the 
presence of rP21 showed a reduction in cell number. (B) rP21 inhibited EC proliferation at 24, 48 and 72 h 
post-treatment and (C) promoted a significant decrease in the 2N cell number and increased the cell number 
in S phase at 72 h post-treatment. Data are expressed as mean ± standard deviation. Significant differences were 
determined using one-way ANOVA and Tukey’s multiple comparisons test (A–C). Differences were considered 
significant when p < 0.05.
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physiological functions including regulation of the actin cytoskeleton, control of cell shape, adhesion, lamellipo-
dia formation, motility and modulation of signal transduction pathways. Ezrin plays a key role in the actin-based 
cellular functions required for cell locomotion that are important in angiogenesis56–58.
Literature shows that different ABPs play critical roles in regulating the complex series of signaling events in 
ECs to shape the changes that occur during migration and angiogenesis. In this context, the results of our 2-D cell 
cultures showed that rP21 is able to up-regulate the expression of genes that are required for actin polymerization, 
stress fiber formation and migration such as cofilin, cortactin, AFAP1, AFAP1L1, and fascin. However, when 
gene expression levels from 3-D cell cultures were determined essentially the very genes that were overexpressed 
in 2-D cultures did not show altered expression or were down-regulated by the rP21 treatment, with the excep-
tion of gelsolin and moesin at 24 h, which were slightly up-regulated. Interestingly, ezrin (ERM protein family) 
expression was significantly down-regulated in both cell culture systems. The negative modulation of ezrin may 
be directly related to the inhibition of blood vessel formation. This hypothesis is corroborated by Zhao et al.59 that 
showed that silencing of the ezrin gene in human umbilical vein endothelial cells (HUVECs) in vitro suppressed 
migration and angiogenesis.
It is known that the cytoskeletal organization within ECs in 2-D cell cultures is distinct from that in 3-D 
cultures36,59–63. Growing evidence from 2-D model systems has suggested that mechanical substrates (i.e., rigid 
glass or polystyrene substrates) promote changes in migration, proliferation, differentiation and cell shape. 
However, it remains unclear whether these physiological processes may be generalized to 3-D cultures or 
in vivo systems59,60,64. It has clearly been shown that ECs extend sprouts into an intact 3-D ECM whereas ECs form 
a thin monolayer upon a mechanical substrate. Therefore, ECs behave differently when grown in 3-D cultures 
compared to 2-D cultures36. In this sense, the differences in gene expression profiles observed in our data may be 
due changes in the matrix composition that can directly or indirectly influence myosin-driven, actin-mediated 
contractility, cell motility, cell-cell interactions and/or intracellular signaling pathways61.
rP21 modulates expression of angiogenesis-associated genes. To assess the effect of rP21 on gene 
expression profiles of pro- and anti-angiogenic molecules, tEnd cells were plated in 24-well plates that had been 
previously coated with a thin layer of extracellular matrix (3-D system) or not (2-D system) and incubated with 
rP21 or culture medium (control group) for 24 and 72 h. After 24 h of treatment in 2-D culture, rP21 up-regulated 
the expression of matrix metalloproteinase 9 (MMP9) and soluble fms-like tyrosine kinase 1 (sFlt-1). However, 
rP21 did not alter vascular endothelial growth factor receptor-1/fms-like tyrosine kinase (VEGFR1/Flt1) and vas-
cular endothelial growth factor A (VEGFA) expression. At 72 h, rP21 continued to up-regulate sFlt-1 expression. 
Interestingly, rP21 promoted a positive modulation of VEGFA expression and did not influence MMP9 and Flt-1 
Figure 4. rP21 induces actin cytoskeleton polymerization in ECs. (A) Different concentrations of rP21 
significantly increased F-actin levels in tEnd cells compared to the untreated group and (B) representative 
images are shown. Bars: 50 μ m. (C) rP21 treatment promoted faster recovery of the actin filaments compared 
to the control groups, confirming that rP21 promotes actin polymerization. (D) Representative images 
highlighting the different actin cytoskeleton morphologies where rP21-treated tEnd cells exhibited thick 
actin fibers and sites of lamellipodial membrane protrusions enriched in F-actin compared to the control 
group (white arrows). Bars: 10 μ m. The data are expressed as the means ± standard deviations of experiments 
performed in triplicate. Significant differences were determined using one-way ANOVA with Tukey’s multiple 
comparisons test (A,B). Differences were considered significant when p < 0.05.
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expression at 72 h (Fig. 6A). In 3-D cell cultures, rP21 increased the expression levels of sFlt-1 at 24 h and MMP9, 
sFlt-1, and VEGFA at 72 h and decreased the expression levels of VEGFA at 24 h and Flt-1 at 72 h (Fig. 6B).
Angiogenesis is known to be controlled by the balance between various pro- and anti-angiogenic signals. 
MMP9 is an enzyme expressed in many cell types, including ECs, and has the capacity to degrade many molecules 
of the ECM. Several studies have shown that this metalloproteinase is implicated in the pro-angiogenic process in 
various ways65–68. However, the role of MMP9 during angiogenesis remains uncertain69.
VEGFA belongs to the mammalian platelet-derived growth factor (PDGF) family and acts as a potent, mul-
tifunctional cytokine that induces colony formation by recruiting mature subsets of cells. It also plays an active 
role in the regulation of the physiological and pathological growth of blood vessels formed during angiogenic and 
vasculogenic processes70. VEGFA binds to VEGFR1 (Flt-1) with an affinity that is approximately 10-fold higher 
than that of Flk-1/KDR (VEGFR2)71. VEGFR1 and VEGFR2 are members of the VEGFR tyrosine kinase (TK) 
family and are highly expressed in ECs. Flt-1 is alternatively spliced to produce both a membrane-localized and 
Figure 5. rP21 modulates the expression of actin-related genes in ECs. (A) Differential expression of actin-
related mRNAs in tEnd cells was analyzed by RT-qPCR after 24 and 72 h of rP21 stimulation in 2-D and (B) 
3-D cell cultures. Data are expressed as means ± standard deviations of experiments performed in triplicate. 
Significant differences were determined using Student’s t-test (two-sided) and Mann-Whitney test. Differences 
were considered significant when p < 0.05.
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a soluble form (sFlt-1) that are secreted by ECs. Shibuya and Claesson-Welsh71 showed that VEGFR1-null mice 
exhibited overgrowth and dysmorphogenesis of blood vessels which suggests that Flt-1 is a negative regulator of 
angiogenesis during embryonic development. Takeda et al.72 also revealed the negative regulatory role of Flt-1, 
as knockout mice exhibited embryonic lethality due to the overgrowth of ECs and blood vessel dysfunction. 
In addition, Amano et al.73 showed that a knockout mouse lacking the Flt-1 intracellular TK domain exhibited 
impaired angiogenesis after hind limb ischemia indicating that Flt-1 signaling is essential for ischemia-related 
re-vascularization. Furthermore, Murdoch et al.74 showed that the induction of sFlt-1 expression is relevant to 
the recovery of suppressed blood flow following hind limb ischemia. It is known that sFlt-1 retains high affinity 
for VEGFA75 and can trap VEGFA to prevent it from binding to VEGFRs. These results suggest that soluble Flt-1 
modulates the amount of VEGFA76 and inhibits VEGFA activity without affecting the intracellular signaling path-
ways of VEGFRs73. Thus, Flt-1 negatively regulates angiogenesis through its extracellular domain and positively 
regulates angiogenesis through its tyrosine kinase domain.
According to the results of the 3-D cellular culture system, we suggest that the anti-angiogenic activity of rP21 
at 24 h is related to the up-regulation of sFlt-1 expression and the negative modulation of VEGFA. However, at 
72 h we observed a decrease in sFlt-1 expression and increase in VEGFA and MMP9 expression in rP21-treated 
ECs. Interestingly, at this time point we observed that rP21 strongly down-regulated Flt-1 expression that may be 
related to the negative regulation of angiogenesis in agreement with the studies mentioned above. In this sense, 
the initial inhibition of angiogenesis by rP21 at 24 h could explain the increased sFlt-1 levels and the continued 
inhibition of angiogenesis at 72 h is likely related to the down-regulation of Flt-1. In the 2-D system, rP21 posi-
tively regulated the pro- and anti-angiogenic signals. However, it is known that the cells have different behaviors 
that depend on the conditions of the cell culture model system.
In order to support our gene expression results, we performed immunoblotting analysis of ezrin and Flt-1 
protein expression in 2-D or 3-D cultured cells treated or not with rP21. Our results showed decreased expression 
of ezrin in 2-D cultured cells treated with rP21 (Fig. 7A). Also, we observed a significant decrease in Flt-1 protein 
content from 3-D cells previously treated with rP21 (Fig. 7B).
Potential P21-mediated mechanism during CCC pathogenesis. Combining our findings and the 
current literature, we hypothesize that an anti-angiogenic mechanism is triggered by P21 during CCC onset 
and progression. We propose that P21 is continuously secreted to the extracellular space by intracellular amas-
tigotes located in cardiac fibers that induces leukocyte recruitment to the site of inflammation and up-regulates 
Figure 6. rP21 modulates the expression of angiogenesis-associated genes. (A) Gene expression profiles 
of pro- and anti-angiogenic molecules after 24 and 72 h of rP21 stimulation in 2-D and (B) 3-D cell cultures. 
The data are expressed as the means ± standard deviations of experiments performed in triplicate. Significant 
differences were determined using Student’s t-test (two-sided) and Mann-Whitney test. Differences were 
considered significant when p < 0.05.
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IL-4 expression15. It is known that IL-4 induces macrophages to acquire alternative (M2) activation that is char-
acterized by increased production of sFlt-1 (anti-angiogenic molecule)77. Moreover, we believe that P21 has 
the capacity to bind to CXCR4+ ECs from the heart. P21-sensitized ECs would lose their capacity to promote 
re-vascularization in situ through a cascade of intracellular events such as inhibition of EC proliferation, sFlt-1 
overexpression, and down-regulation of Flt-1, ezrin, AFAP1, AFAP1L1 and moesin, that could partially explain 
the functional and structural micro-vascular abnormalities observed in CCC13 (Fig. 8).
Experimental procedures. Cell line and culture. A murine EC line derived from a thymus hemangioma 
(tEnd) was used as established by Bussolino et al.78 and Achê et al.79 with some modifications. Cells were culti-
vated in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS, 2 mM l-glutamine, 2 mM 
sodium pyruvate, 1 mM non-essential amino acids, 100 U/mL penicillin and 100 μ g/mL streptomycin and incu-
bated at 37 °C in a humidified atmosphere containing 5% CO2.
rP21 purification. rP21 (GenBank: EU004210.1) was purified as previously described by Dos Santos et al.80.
Matrigel tube formation assay. The influence of rP21 on EC tube formation was evaluated as previously 
described81, with modifications. tEnd cells (5 × 105 cells/well) were pre-incubated with rP21 (40 μ g/mL), 
AMD3100-CXCR4 inhibitor (30 μ M) or culture medium for 30 minutes at 37 °C. To evaluate whether 
anti-angiogenic activity of rP21 occurs by direct interaction with EC, tEnd cells pre-incubated with rP21 (40 μ g/mL) 
were also washed out with PBS and centrifuged (5 min, 1500 RPM). After treatment, cells were seeded at 24-well 
plates that had previously been coated with 50 μ L of 5.25 mg/mL Matrigel (BD Bioscience) and incubated with 
medium supplemented with bFGF (30 ng/mL). After 24, 48 and 72 h of incubation at 37 °C and 5% CO2, images 
were acquired at 20x magnification using a brightfield microscope and the number of vessels counted15.
Degradation of ECM components. Degradation of ECM components was assayed as previously described18,82. 
To evaluate the fibrinogenolytic activity 50 μ L of bovine fibrinogen sample (1.5 mg/mL in PBS, pH 7.8) was incu-
bated with different amounts of rP21 (5, 10, 20 and 40 μ g) for 1 h at 37 °C. The reaction was stopped with 25 μ L 
stop solution (0.06 M Tris-HCl, pH 6.8, containing 10% (v/v) glycerol, 10% (v/v) β -mercaptoethanol, 2% (w/v) 
SDS and 0.05% (w/v) bromophenol blue). Samples were then heated at 100 °C for 5 minutes and analyzed by 
12.5% (w/v) SDS-PAGE.
Matrigel (5.25 mg/mL) or a fibronectin solution (1 mg/mL in 50 mM Tris-HCl, pH 7.4) was incubated with 
40 μ g of rP21 at 37 °C for 1 h. The reaction was stopped by adding stop solution, samples were heated, and the 
substrate digestion was analyzed by 7% SDS-PAGE (w/v), as mentioned above.
Protein binding and internalization assay. Direct interaction of rP21 with ECs was assessed as previously 
described83,84. tEnd cells were seeded at a density of 2.5 × 104 cells/coverslip in 24-well micro-plates and were then 
incubated with rP21 for 24 h. After washing, cells were fixed with 4% paraformaldehyde for 1 h at room temper-
ature and washed three times with PBS. Cells were incubated overnight with an anti-rP21 primary polyclonal 
rabbit antibody (diluted 1:200 in PGN-0.01% saponin solution). Then, coverslips were washed and incubated with 
Alexa Fluor 488-conjugated anti-rabbit IgG (1:200 in PGN + saponin), tetramethyl rhodamine isothiocyanate 
Figure 7. rP21 treatment interferes in the expression of actin cytoskeleton and angiogenesis-related 
proteins. (A) After 24 and 72 h, rP21 promoted a robust reduction in ezrin expression (2-D system) and (B) 
Flt-1/VEGFR-1 (3-D system). Actin was used as a loading control. Cropped blots are displayed.
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(TRITC)-conjugated phalloidin (diluted 1:500 in PGN + saponin) and 4,6′ -diamidino-2-phenylindole dilactate 
(DAPI, Invitrogen, USA) (diluted 1:500 in PGN + saponin) for 1 h. Coverslips were mounted on glass slides and 
samples were analyzed by confocal fluorescence microscopy (Zeiss, LSM 510 Meta, Germany) using an inverted 
microscope (Zeiss Axiovert 200 M).
CXCR4 receptor expression in endothelial cells. To examine CXCR4 receptor expression tEnd cells (1 × 106 cells) 
were fixed with 4% formaldehyde for 1 h washed with PBS and then stained with an anti-CXCR4 HU CD184 BV 
421 12G5 50 TST antibody diluted in PBS. Samples were analyzed in a FACSCantoII (BD) and the results were 
obtained using FlowJo software (version 7.6.3).
Proliferation assays. tEnd cells were seeded at a density of 1.0 × 104 cells in 24-well micro-plates. After adhesion, 
cells were incubated with culture medium or rP21 (40 μ g/mL) for 24, 48 and 72 h at 37 °C. Following treatment, 
cells were harvested and counted in Neubauer chamber.
Additionally, the proliferation of the rP21-treated tEnd cells also was evaluated using MTT (3-(4,5-dimet
hylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay83. Briefly, cells were seeded at a density of 1 × 104 cells/
well in 96-well micro-plates. After adhesion, cells were grown in medium supplemented with FBS and bFGF in 
the presence or absence of 40 μ g/mL rP21 for 24, 48 and 72 h at 37 °C and 5% CO2. As a negative control, cells 
were grown in growth factor- and FBS-free medium. After treatment, cells were incubated with 5 mg/mL MTT 
for 3 h at 37 °C. Formazan crystals resulting from MTT reduction were dissolved by the addition of 100 μ L of 
phosphate-buffered saline (PBS) containing 10% SDS and 0.01 M HCl (18 h, 37 °C and 5% CO2). Absorbance 
(550 nm) was measured on a multi-well scanning spectrophotometer (Thermo Scientific).
Cell cycle analysis. Cell cycle was analyzed by quantifying the DNA content as previously described85,86. Briefly, 
tEnd cells were plated at a density of 0.25 × 105 cells/well in 24-well micro-plates and after adhesion cells were 
treated with rP21 (40 μ g/mL) or culture medium (control group) for 24, 48 and 72 h at 37 °C and 5% CO2. Then, 
cells were harvested and fixed in 70% ethanol overnight at 4 °C. To ensure that only the DNA was stained, cells 
were incubated with RNase A (100 μ g/mL) and propidium iodide (PI) (10 μ g/mL) for 45 minutes at 37 °C. Cell 
cycle was analyzed in a FACSCantoII (BD) and the data were obtained using FlowJo software (version 7.6.3).
Figure 8. Potential P21-mediated mechanism during CCC pathogenesis. P21 is continuously secreted to 
the extracellular space by intracellular amastigotes located in cardiac fibers and induces leukocyte recruitment 
to the site of inflammation and up-regulates IL-4 expression. IL-4 induces macrophages to acquire alternative 
(M2) activation that is characterized by increased production of sFlt-1 (anti-angiogenic molecule). Moreover, 
P21-sensitized CXCR4+ ECs would lose their capacity to promote in situ re-vascularization through a cascade 
of intracellular events such as inhibition of EC proliferation, sFlt-1 overexpression, and down-regulation of Flt-
1, ezrin, AFAP1, AFAP1L1 and moesin. PCBT have drawn the figure.
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F-actin staining and actin recovery assay. F-actin accumulation and distribution were determined as described87. 
tEnd cells were seeded at a density of 2.5 × 104 cells/coverslip in 24-well micro-plates. After adhesion, cells were 
treated with different rP21 concentrations (20, 40, and 80 μ g/mL) or culture medium (control group) for 90 min 
at 37 °C and 5% CO2. Then, cells were fixed with 4% formaldehyde for 1 h at room temperature and covers-
lips washed three times with PBS. Cells were incubated with TRITC-conjugated phalloidin (diluted 1:500 in 
PGN-0.01% saponin solution) and DAPI (diluted 1:500 in PGN + saponin) for 1 h to label F-actin and nuclei, 
respectively.
F-actin recovery experiment was performed as previously described87,88. tEnd cells were seeded at a density 
of 2 × 104 cells/coverslip in 24-well micro-plates. After adhesion, cells were treated with 1.5 μ M cytochalasin-D (a 
pharmacological inhibitor of actin subunit assembly at the filament barbed ends) for 40 minutes to induce actin 
disassembly, followed by a 90 min recovery period in the presence of rP21 (40 μ g/mL) or culture medium (control 
group), during which F-actin would be re-assembled. Then, cells were submitted to the same labeling conditions 
described above. In both experiments, the coverslips were mounted on glass slides and images captured with a 
63× oil immersion objective using an inverted fluorescence microscope (Zeiss Axiovert 200 M). Digital images 
were analyzed using confocal fluorescence microscopy software (Zeiss, LSM 510 Meta, Germany) and the mean 
F-actin fluorescence was determined by setting a high threshold in ImageJ software (National Institutes of Health, 
USA)88.
Gene expression. For the real-time PCR experiments, tEnd cells (1 × 104 cells/well) were seeded in 24-well 
micro-plates that had previously been coated with a thin ECM (3-D cell culture system) or not (2-D cell culture 
system). Cells were then incubated with rP21 (40 μ g/mL) or culture medium (control group) for 24 and 72 h. 
Total RNA was extracted using a RiboZol™ Plus RNA Purification Kit (Amaresco) and a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) was used for reverse transcription according to the manufactur-
ers’ instructions. Quantitative RT-PCR was performed using an ABI 7300 system (Applied Biosystems) and SDS 
v1.4.1 Software (Applied Biosystems) was used to analyze the received data. Reaction consisted of 5 μ L of SYBR® 
Green PCR Master Mix (2X) (Applied Biosystems), 10 μ M forward and reverse primers (0.5 μ L F + 0.5 μ L R), 
4 μ L of nuclease-free water, and 2 μ L of cDNA (125 ng/μ L) in a total volume of 12 μ L per reaction/sample. The 
following thermal cycling protocol was used, as recommended by the manufacturer: 95 °C for 10 min, 95 °C for 
15 seconds and 60 °C for 1 min for 40 cycles. The cycles were followed by a melting curve analysis at 95 °C for 
15 seconds and 60 °C for 1 min.
Primer sequences were designed using sequence alignments obtained from GenBank (NIH/NCBI) based 
on the published RNA sequences (Supplementary Table 1). Data were normalized using Beta-2 microglobulin 
(β 2M) as a housekeeping gene and then analyzed via the comparative threshold cycle (CT) method to calcu-
late fold changes in expression in rP21-treated groups compared to the control group where ∆ CT = the CT of 
gene of interest minus the CT of B2m and ∆ ∆ CT = ∆ CT of the rP21-treated groups minus the ∆ CT of culture 
medium-treated groups. The fold changes in gene expression for the rP21-treated groups were then calculated as 
2∆∆CT. All real-time experiments were performed with biological and technical triplicates.
Immunoblotting analysis. To determine protein expression, tEnd cells were seeded in 24-well micro-plates that 
had previously been coated with a thin ECM (3-D cell culture system) or not (2-D cell culture system). Cells were 
then incubated with rP21 (40 μ g/mL) or culture medium (control group) for 24 and 72 h. Following PBS washes, 
cells were harvested in RIPA (Radioimmunoprecipitation) Lysis Buffer (pH 7.4) (Santa Cruz Biotechnology) 
containing 200 mM PMSF (phenylmethane sulfonyl fluoride), protease inhibitor cocktail and 100 mM sodium 
orthovanadate. After sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electropho-
retic protein transfer, the membrane was incubated with monoclonal anti-Ezrin (Sigma-Aldrich/E 8897) and 
VEGFR-1/Flt-1 antibody (R&D Systems/AF471) (gifts from Professor Ricardo José Giordano, Universidade 
de São Paulo, Brazil) followed by horseradish peroxidase-conjugated secondary antibody (Sigma-Aldrich). 
Immunoreactive signals were visualized by using enhanced chemiluminescence (Amersham), and densitome-
try performed using UVIBAND image quantification software. Loading controls of extracts were checked with 
anti-actin antibody (Sigma-Aldrich).
Statistical analysis. Data are expressed as mean ± standard deviation of experiments performed at least three 
times in triplicate. All data were first checked for normal distribution. Significance differences were determined 
by one-way ANOVA, Tukey’s multiple comparisons test and Student’s t-test (two-sided) for the parametric data or 
the Mann-Whitney test for nonparametric data according to the experimental design (GraphPad Prism Software 
version 6.01). Data were considered statistically significant at p < 0.05.
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